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Introduction: Primary biliary cirrhosis is an autoimmune disease that tends to progress to fibrosis and cirrhosis with
hepatic failure. Primary biliary cirrhosis is often associated with other non- hepatic autoimmune diseases. An
association with rheumatoid arthritis has been suggested to coexist in 1.8% to 5.6% of patients with primary biliary
cirrhosis, but data supporting this association are scarce. The etiologic and pathogenetic mechanisms are not yet
fully understood and several factors have been implicated. The therapeutic management must consider the two
pathologies.
Case presentation: We describe the case of a 60-year-old Moroccan woman with severe erosive rheumatoid
arthritis and primary biliary cirrhosis treated with rituximab. During treatment, we observed a good clinical and
biological response of her rheumatoid arthritis but persistent abnormal liver function tests.
Conclusion: B cells seem to play a major role in the pathogenesis of both rheumatoid arthritis and primary biliary
cirrhosis. Additional studies are necessary to better determine the therapeutic role of rituximab in both diseases.Introduction
Primary biliary cirrhosis (PBC) is an autoimmune disease
characterized by chronic destruction of bile ducts that can
lead to liver cirrhosis. It can be accompanied or preceded
by various autoimmune disorders [1]. PBC can be associ-
ated with Sjögren’s syndrome in 70% of patients [2], auto-
immune thyroid disease in about 10%, and systemic
sclerosis in 15% [3]. The association of PBC with rheuma-
toid arthritis (RA) is exceptional, and the true prevalence
of PBC in RA is not well known [4]. This may impose
several therapeutic and diagnostic challenges. In both
diseases, it was observed that B cells played a promin-
ent role in pathogenesis [5]. We describe an unusual
case of a patient with PBC and RA treated with
rituximab.
Case presentation
A 60-year-old woman was diagnosed with PBC in 2004.
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reproduction in any medium, provided the orbiopsy that revealed signs of nonsuppurative cholangitis
without fibrosis or cirrhosis and on laboratory tests
showing high levels of alkaline phosphatase (four times
the upper normal limit) and gamma-glutamyltransferase
(three times the upper normal limit); positive type 2 anti-
mitochondrial antibodies (1:640) serological tests were
negative for hepatitis B and C. She was treated with
ursodeoxycholic acid (UDCA) at a dose of 12mg/kg
(600mg/day), with partial regression of her hepatic
disorder. One year later, our patient presented with a
deforming polyarthritis of her small and large joints. A
physical examination on admission found synovitis in
nine joints, seven painful joints, bilateral ulnar deviation
hand deformities, Z-thumb deformity, and a limitation
of motion in her wrists, shoulders and left hip.
Laboratory tests showed that our patient had an in-
flammatory syndrome with an erythrocyte sedimentation
rate of 81mm at the first hour and a C-reactive protein
level of 14mg/L. Her rheumatoid factor was positive at
143IU/L, and she had an anti-citrullinated protein anti-
body level of 798UI/mL. Radiographs showed erosions of
her metacarpophalangeal and metatarsophalangeal joints,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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left coxitis. Based on this clinical, biological and radio-
logical evidence, a diagnosis of active and severe RA was
made. Our patient was treated with a low dose of metho-
trexate (MTX; 7.5mg/week) associated with rituximab
(two doses of 1000mg separated by two weeks), which
demonstrated good efficiency in her arthritis after five
months of follow-up (Disease Activity score-28 of 2.8), but
her abnormal liver function tests persisted.
Discussion
The association of PBC with RA is rare and not clear,
although several studies since the 1970s have pointed
to a possible association. However, the true prevalence
of PBC in RA is not well known. A study of 172 pa-
tients with PBC confirmed that a relatively large pro-
portion of patients with PBC have an autoimmune
rheumatic disease [6]. We found that scleroderma was
the most common connective tissue disease associated
with PBC [3-6]. In a Japanese review, three of the 54
patients with PBC had polyarthritis, although the au-
thors did not specify whether or not RA criteria were
fulfilled [7]. The studies suggest that the prevalence of
RA in PBC patients is between 1.8% and 5.6% [6]. Fur-
ther studies are needed to determine the relationship
between these two diseases; in particular, an investiga-
tion of PBC occurrence in large RA patient cohorts is
needed.
The case described here illustrates the possible associ-
ation of RA and PBC. The etiologic and pathogenetic
mechanisms of PBC are not yet fully understood and
several factors have been implicated. Among them, it
has been suggested that B cells may have different roles
in the induction of PBC [3-8]. Both B-cell and T-cell
responses to the E2 subunit of the inner mitochondrial
membrane enzyme pyruvate dehydrogenase complex
have been documented in PBC and implicated in its
pathogenesis [9]. The serological hallmark of PBC is the
presence of anti-mitochondrial autoantibodies, especially
to the E2 subunit of pyruvate dehydrogenase complex,
which are present in 90% to 95% of patients with PBC.
In addition, patients with PBC often have elevated serum
levels of total immunoglobulin M, and B cells from pa-
tients with PBC produce significantly greater amounts of
immunoglobulin M when stimulated with CpG-B com-
pared with those from healthy controls [10]. Further-
more, treatment with anti-cluster of differentiation 20
monoclonal antibody resulted in amelioration of liver in-
flammation, supporting a potential mechanism of action
for B-cell-targeted therapies in PBC.
The association between PBC and RA has raised ques-
tions about the hepatotoxicity of RA drugs [11]. In this
case, we examined the effects on safety and immuno-
logical selective B-cell depletion using rituximab (ananti-cluster of differentiation 20 monoclonal antibody)
with low-dose MTX in a patient with PBC and RA.
MTX has been previously tested as a treatment of
PBC, especially when conventional UDCA monotherapy
is ineffective [4-11]. Conflicting data have been reported,
but a recent 10-year follow-up study suggested that
MTX plus UDCA was more effective than UDCA alone
in terms of survival without liver transplantation [4].
In an open study, six patients with PBC and incom-
plete responses to UDCA were treated with two doses of
1000mg rituximab two weeks apart and followed for 52
weeks. The results of this study showed that rituximab
was as safe and well-tolerated in patients with PBC as in
patients with other indications, suggesting that rituxi-
mab has a potential therapeutic effect in this subgroup
of patients without optimal responses to UDCA [5]. An-
other case reported on a 50-year-old patient with RA
and PBC who was treated with rituximab and showed
clinical and laboratory improvement in the first six
months of treatment [12]. In our patient, we used a
small amount of MTX (7.5mg/week) combined with two
doses of 1000mg of rituximab, two weeks apart. After
five months of follow-up, we observed a good clinical
and biological response of her RA although there were
persistent abnormalities in her liver tests.
The proinflammatory cytokine tumor necrosis factor
alpha seems to play a major role in the pathogenesis of
both RA and PBC. Spadaro et al. described the case of a
46-year-old patient with RA and PBC who was treated
with anti-tumor necrosis factors [13]. During infliximab
treatment, the authors observed a poor clinical response
and persistence of liver function test abnormalities. After
infliximab interruption, their patient’s levels of alkaline
phosphatase dropped and had nearly reached normal
values when etanercept was started. The etanercept
maintained the patient’s liver enzyme levels within the
normal range and controlled the arthritis during follow-
up of 30 months, in contrast to the infliximab [13]. An-
other two cases have been reported where the patients
were treated with etanercept and MTX 4mg/week,
obtaining a significant improvement in disease activity
and liver function, maintained one year after starting
etanercept [14,15].
Our case report suggests that additional studies are
needed to determine which treatment is safest and will
demonstrate greater efficiency in both diseases.
Conclusion
The association of RA and PBC is rarely reported in the
literature. Studies are needed to determine the preva-
lence of this association. Recognition of the pathogenetic
mechanism could have a tremendous impact on the
appropriate care of patients and the choice of medica-
tion to treat both RA and PBC.
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